The Illumina mission is to improve human health by unlocking the power of the genome. Now, through innovation and collaboration, we are enabling genomic breakthroughs in immunotherapy, biomarker discovery, and therapy selection. The opportunity to transform tumor profiling with innovative assays that enable comprehensive genomic profiling, new companion diagnostic development, and liquid biopsy inspires us to push boundaries and drive innovation.
Join us on Twitter on Monday, November 16, 9:00 am PST, for a live Q&A event to learn more about a simpler, faster and more scalable CGP workflow from Illumina’s own product team. Follow @IlluminaLive on Twitter to receive updates around our AMP events.
The following workshops will be available on-demand as of November 10, 2020.
Nikoletta Sidiropoulos, MD
Associate Professor & Director Molecular Pathology,
University of Vermont, Larner College of Medicine
Chief Scientific Officerand Director Genomics Technologies,
OmniSeq Inc., Roswell Park Comprehensive Cancer Center
Jeremy Wallentine, MD
Chris Karlovich, PhD
Associate Director of the Molecular Characterization Lab (MoCha), Frederick National Laboratory for Cancer Research
Jonathan Chen, MD PhD
Instructor in Pathology,
Department of Pathology,
Massachusetts General Hospital
Jaclyn Hechtman, MD
Associate Attending Pathologist,
Memorial Sloan Kettering Cancer Center
Jodi M. Carter, MD PhD
Assistant Professor of Laboratory Medicine and Pathology,
Department of Laboratory Medicine and Pathology,
Infectious Disease Specialist,
Click to learn more about Illumina’s solutions.
Trusight Oncology 500 Portfolio Updates: